

## Bio Asia 2026 records highest number of delegates and discussions

18 February 2026 | News

**For Bio Asia 2026, over 120 startups were shortlisted by an eminent jury**



BioAsia 2026, the 23rd edition of Asia's premier life sciences and health-tech forum, concluded successfully on 18 Feb, reaffirming its position as a catalyst for global collaboration, innovation, and strategic partnerships in the life sciences and TechBio ecosystem.

This year's event witnessed participation from over 4500 delegates and visitors (Highest Ever), including global delegates, speakers, all exploring the latest advancements and forging transformative partnerships. This edition facilitated 4000 + high impact B2B meetings, unlocking new collaborations and investment opportunities.

For Bio Asia 2026, over 120 startups were shortlisted by an eminent jury. 40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions, reinforcing Telangana's position as an innovation hub of life sciences.

Most innovative startups that received BioAsia 2026 Innovation Awards were Achala Health Services Private Limited, Exquinz Life Sciences Pvt Ltd, Helex, Natural Solutions & Nutraceuticals Pvt Ltd and Sree Guravey Life Sciences OPC Pvt Ltd.

D. Sridhar Babu, Hon'ble Minister for Industries and Commerce, Government of Telangana, said, "By far, this has been the most successful edition of Bio Asia to date, creating pathways to global partnerships, fostering innovation in AI, automation, cell and gene therapies, and advanced manufacturing. The state has seen significant international engagement this year, with global companies from France, Indonesia, the USA and Novartis celebrating Hyderabad as a key hub for investment and

innovation."

According to Sanjay Kumar (IAS), Special Chief Secretary, Industries and Commerce, Government of Telangana, "The state's focus on advanced therapeutics, digital health, precision medicine, AI-driven drug discovery, and CRDMO innovations ensures a robust ecosystem that is future-ready and globally competitive. By combining policy foresight with strong infrastructure and regulatory support, Telangana is fostering a collaborative environment that will continue to drive transformative impact in the life sciences sector."

Shakti M Nagappan, CEO, Telangana Life Sciences, added, "This edition of Bio Asia 2026 was the most successful edition of the marquee Life Sciences Seminar, recording the highest number of delegates and discussions. The partnerships forged and avenues created at Bio Asia 2026 will act as a catalyst to drive the next phase of Innovation Led Growth in Telangana's Life Sciences journey."